

GRIFOLS

Grifols acquires 25 U.S.-based plasma centers from BPL ensuring one million additional liters for fractionation

- Grifols will immediately increase its plasma supply following the acquisition of these 25 plasma centers, which obtain a run-rate of 1 million liters of plasma per year
- The USD 370 million transaction will be financed from Grifols' own resources
- This acquisition promotes the global expansion and plasma-supply diversification strategy of the company, an industry leader with 344 plasma centers worldwide: 289 in the U.S. following this transaction and 55 in Europe
- Grifols remains committed to increasing its supply of plasma and plasma-derived therapies to ensure patients continue to receive the treatments and healthcare they need

Barcelona, March 1, 2021.- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies dedicated for more than 100 years to enhancing people's health and well-being, finalized a USD 370 million transaction to acquire 25 U.S.-based plasma donation centers from BPL Plasma Inc., a subsidiary of Bio Products Laboratory Holdings Limited. The transaction has received the applicable regulatory clearances and will be financed with Grifols' own resources, without issuing debt.

In accordance with the company's strategic plan to advance its plasma-collection leadership, this transaction expands, reinforces and diversifies Grifols' already-robust network of centers and capacity to supply life-enhancing plasma-derived medicines to patients.

In parallel, the transaction also builds on its network of plasma centers, which represents an important competitive advantage. Grifols remains committed to increasing the availability of its essential plasma-derived products to meet growing demand.

Grifols was able to limit its net plasma supply impact by roughly 15% in 2020 despite of COVID-19-related constraints. In 2021, the company is ready for a rebound in its plasma-collection levels in the wake of wider vaccination deployments and the ease of COVID-19 constraints. Grifols is also advancing on the execution of its expansion plan, comprising organic and inorganic growth.

GRIFOLS

As part of its organic efforts, the company plans to open between 15 and 20 new plasma centers in 2021. Thanks to its agile management, Grifols will open several plasma centers in Egypt in 2021, following the strategic alliance signed with the Egyptian government in November 2020.

Grifols now operates 344 plasma centers worldwide: 289 in the U.S. and 55 in Europe across Germany, Austria and, recently Hungary. The 25 centers acquired from BPL are authorized by the U.S. Food and Drug Administration (FDA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

Grifols retained the legal services of Osborne Clarke, S.L.P. for this transaction.

Expanding its plasma supply to ensure patients' access to treatments

Plasma-derived medicines are used to treat or prevent serious disorders or diseases in a range of therapeutic areas, including pulmonology, hematology, immunology and neurology.

Grifols is making every effort to increase its supply of plasma and plasma-based therapies to ensure patients continue to receive the treatments and healthcare they need. The company also joined global appeals to mobilize all qualified individuals to donate plasma, including both patients recovered from COVID-19 and those unaffected by the virus, given its critical role in the production of life-saving plasma-derived medicines.

Investor contact:

Investor Relations

inversores@grifols.com - investors@grifols.com

Phone number: +34 93 571 02 21

Media contacts:

Spain: Raquel Lumbreras Raquel_lumbreras@duomocomunicacion.com Borja Gómez Borja_gomez@duomocomunicacion.com Duomo Comunicación – Grifols PR office Tel. +34 91 311 92 89 - 91 311 92 90	International: Brad Pick Brad.pick@grifols.com Grifols Corporate Communications
---	---

GRIFOLS

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with close to 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2020, Grifols' economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.